You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The health IT and precision oncology arm of Patrick Soon-Shiong's NantWorks conglomerate narrowed its quarterly net loss by 32 percent during the quarter.
Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
Carebox's system matches eligibility criteria from clinical trial databases with patients' health and genomic data to identify potentially relevant studies.
PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.
As labs without prior molecular testing or high-volume testing experience bring SARS-CoV-2 testing online, some are finding that an LIS upgrade is in order.
The nanopore sequencing-based test is designed to both diagnose SARS-CoV-2 infection, as well as monitor mutations that may affect efforts to combat the virus.
The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.
The test will use a Gauss-developed mobile phone app that provides instructions on sample collection and provides results within 15 minutes.
Cernostics offers an assay that analyzes whole-slide digital images with multiplexed fluorescence to help interpret Barrett's esophagus patient biopsies.
The New York startup is curating available data for all Emergency Use Authorized molecular diagnostic tests for the benefit of the public.
Up to 35 private and public labs in France will be able to use UgenTec's FastFinder analysis software to scale up testing for SARS-CoV-2 and other pathogens.
The computational method, reported in Science Translational Medicine, enables the de novo prediction of cancer-associated T-cell receptors for cancer detection.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.